Rhovac hires investment bank to generate interest in lead candidate

Biotech company Rhovac is on the lookout for a deal or a partnership regarding its lead candidate. International investment managing firm Stifel Nicolaus Europe has been appointed to help with the task.

Photo: Jens Dresling

Danish biotech company Rhovac, spearheaded by Anders Månsson, former executive of  Leo Pharma and Ferring Pharmaceuticals, has made it its goal to examine the opportunities of either striking a deal or entering a partnership pertaining to its lead candidate RV001, the company reports in a press relase on Monday.

RV001, which is a RhoC based cancer vaccine, was granted the Fast Track Designation by the US Food and Drug Administration (FDA) last year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs